A retrospective study evaluating rare immune related adverse events by immune checkpoint inhibitors in clinical practice
Latest Information Update: 15 Oct 2019
At a glance
- Drugs Atezolizumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Carcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Adverse reactions
Most Recent Events
- 15 Oct 2019 New trial record
- 10 Sep 2019 Results presented at the 20th World Conference on Lung Cancer